Shandong Xinhua Pharmaceutical Co.,Ltd.is the national largest manufacturing and exporting base in the chemical synthetic pharmaceuticals field, it is a leading position in the manufacturing technology and capacity for antipyretics and analgesics in Asia. Nine products have approved by COS;Nine products have approved by FDA.Shandong Xinhua Pharmaceutical I&E Co., Ltd (the company), is sole-subsidiary of Shandong Xinhua Pharmaceutical Co., Ltd. (the mother company). The mother company is a public company listed in HongKong Stock Exchange and Shenzhen Stock Exchange, now is a leading pharmaceutical company has a history of more than 70 years in pharmaceutical community ,with FDA proved facility for 8 APIs and COS certificate for 10 APIs. Xinhua Group also has fine chemicals, which are used in our API synthesis and widely used in many other kinds of industries, such as agrochemicals, dyestuff, PVC stabilizer and etc. The company is engaged in fine chemicals exporting of our Xinhua Group, the chemical site has area of 1.9 million square meters, current capacity for chemical products is around 430, 000mt per year, strongest products includes 1,8-diazabicyclo[5,4,0]undec-7-ene(DBU); Tetramethyl Guanidine(TMG); 6-amino-1,3-dimethyl uracil; 1-phenyl-3-methyl-5-pyrazolone, and etc. DBU and TMG were awarded national patent certificate.
![](https://www.pharmasources.com/static/web/image/news/sssss.png)
more >
Year of Establishment:
1943
Total Assets(USD):
Total Number of Staff:
more than 1000
Main Competitive Advantages:
Other Competitive Advantages:
Patents and Copyrights:
Business Type:
Manufacturer
R&D capacity:
Own Brand
Annual Turnover(USD):
Main Sales Markets:
North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Other Competitive Advantages:
Patents and Copyrights: